分子診断(MDx)の北米市場2021年-2031年

◆英語タイトル:North American Molecular Diagnostics (MDx) Market Report 2021-2031

visiongainが発行した調査報告書(VGA21MA024)◆商品コード:VGA21MA024
◆発行会社(リサーチ会社):visiongain
◆発行日:2021年2月
◆ページ数:353
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:北米
◆産業分野:医療
◆販売価格オプション(消費税別)
Sigle User(1名様閲覧用、1年間、印刷不可)USD4,549 ⇒換算¥673,252見積依頼/購入/質問フォーム
Global Site License(法人閲覧用、1年間、印刷可)USD9,099 ⇒換算¥1,346,652見積依頼/購入/質問フォーム
※visiongain社発行の調査レポートは、Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。

販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行・送付致します。(請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

本調査レポートでは、北米の分子診断(MDx)の市場について調査・分析し、レポート概要、エグゼクティブサマリー、市場動向、技術別(ポリメラーゼ連鎖反応、insituハイブリダイゼーション、等温核酸増幅技術、チップ・マイクロアレイ、質量分析)分析、用途別(腫瘍、薬理ゲノミクス、感染症、遺伝子検査、神経疾患)分析、製品別(機器、試薬)分析、検査場所別(ポイントオブケア(POC)、店頭販売、中央研究所)分析、国別分析、企業情報などの項目を掲載しています。

Growing Prevalence of Infectious Diseases Anticipated to Augur Market Growth
According to the CDC, in the U.S., hospital-acquired infections (HAI) account for over 1.5 million infections & nearly 95,000 associated deaths per year. Molecular diagnostic is critical in the field of infectious disease testing as it provides rapid & successful results. The rising prevalence of infectious diseases & hospital-acquired infections is therefore expected to fuel molecular diagnostics market across the North American region from 2021 to 2031.

Which Factors are Fueling North America Molecular Diagnostics Market Growth?
• Growing Geriatric Population Base
• Increase in Demand for Point-of-Care Facilities
• Growing Prevalence of Target Diseases Such as Genetic, CVDs, and Neurological Diseases
• Introduction of Technologically Advanced Products
Which Factors are Restraining Growth?
• High Prices of Molecular Diagnostics Tests
• Presence of Ambiguous Regulatory Framework to Impede Market Growth
Technological Advancements to Boost Market Growth

According to Visiongain analysis, advancements in technology is projected to boost North American molecular diagnostics industry growth as they provide greater accuracy and are cost-effective. The market is likely to be guided by the launch of MinION, an affordable and compact sequencer that supplies users in small peripheral laboratories and point of care facilities. Also, high demand for over-the-counter diagnostics is expected to help drive market growth in this area. Furthermore, some of the key factors such as advanced cancer diagnostic testing coupled with growing demand for genetic testing is expected to fuel market growth further through 2031.

UNIQUE COVID-19 VARIATIONS– only available in this Visiongain report are dedicated analysis of 4 different rebound scenarios of how the market will develop – no matter how COVID-19 affects the economy.

How do prominent players strengthen their position throughout the world?

You must read this newly updated report if you are involved in this sector. The report from Visiongain shows you potential revenues up to 2031, evaluate information, trends, opportunities and business outlooks.

Discover how to stay ahead

Our 350+ page report provides 500+ tables and charts/graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall North American market and country level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing North America Molecular Diagnostics Market. See how to exploit the opportunities.

Forecasts to 2031 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), SWOT Analysis, PEST Analysis, Porter’s Analysis, product profiles and commercial developments.
Discover sales predictions for the North American market and submarkets

Technology
• Polymerase Chain Reaction
• Multiplex PCR
• Other PCR
• In Situ Hybridization
• Isothermal Nucleic Acid Amplification Technology
• Chips and Microarrays
• Mass Spectrometry
• Sequencing
• Transcription Mediated Amplification
• Others
Application
• Oncology
• Breast Cancer
• Prostate Cancer
• Colorectal Cancer
• Cervical Cancer
• Kidney Cancer
• Liver Cancer
• Blood Cancer
• Lung Cancer
• Other Cancer
• Pharmacogenomics
• Infectious Diseases
• Methicillin-Resistant Staphylococcus Aureus
• Clostridium Difficile
• Vancomycin-Resistant Enterococci
• Carbapenem-Resistant Bacteria
• Flu
• Respiratory Syncytial Virus
• Candida
• Tuberculosis and Drug-Resistant TBA
• Meningitis
• Gastrointestinal Panel Testing
• Chlamydia
• Gonorrhea
• HIV
• Hepatitis C
• Hepatitis B
• Other Infectious Diseases
• Genetic Testing
• Newborn Screening
• Predictive and Presymptomatic Testing
• Other Genetic Testing
• Neurological Disease
• Cardiovascular Diseases
• Microbiology
• Others
Product
• Instruments
• Reagents
Test Location
• Point-of-Care
• Over the Counter
• Central Laboratories
In addition to the revenue predictions for the overall North American market and segments, you will also find revenue forecasts for country by segments as well:
• U.S. Molecular Diagnostics Market
• Revenue Forecasts by Technology
• Revenue Forecasts by Application
• Revenue Forecasts by Product
• Revenue Forecasts by Test Location
• Canada Molecular Diagnostics Market
• Revenue Forecasts by Technology
• Revenue Forecasts by Application
• Revenue Forecasts by Product
• Revenue Forecasts by Test Location

❖ レポートの目次 ❖

1. Report Overview
1.1 Introduction to Molecular Diagnostics Market
1.2 Molecular Diagnostics Market Definition
1.3 Why You Should Read This Report
1.4 What This Report Delivers
1.5 Key Questions Answered By This Analytical Report Include:
1.6 Who is This Report For?
1.7 Methodology
1.7.1 COVID-19 Impact: Recovery Scenarios
1.7.2 Market Evaluation & Forecasting Methodology
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Visiongain Reports
1.10 About Visiongain
2 Executive Summary
3 Market Dynamics
3.1 Drivers
3.1.1 Growing Geriatric Population Base
3.1.2 Increase in Demand for Point-of-Care Facilities
3.1.3 Growing Prevalence of Target Diseases Such as Genetic, CVDs, Neurological Diseases etc.
3.2 Restraints
3.2.1 High Prices of Molecular Diagnostics Tests
3.2.2 Presence of Ambiguous Regulatory Framework to Impede Market Growth
3.3 Opportunities
3.3.1 Technological Advancements to Pave Way for Fresh Revenue Pockets
3.3.2 Growing Demand from Emerging Economies to Offer Lucrative Growth Opportunities
3.3.3 Increase in the Adoption of Automation and Multiplexing of Technologies
3.4 SWOT Analysis
3.4.1 Strengths
3.4.2 Weaknesses
3.4.3 Opportunities
3.4.4 Threats
3.5 Industry analysis – Porter’s
3.5.1 Buyer Power
3.5.2 Supplier Power
3.5.3 Competitive Rivalry
3.5.4 Threat of Substitute
3.5.5 Threat of New Entrants
3.6 Industry analysis – PEST Analysis
3.6.1 Political Factors Impacting Molecular Diagnostics Market
3.6.2 Economic Factors Impacting Molecular Diagnostics Market
3.6.3 Social Factors Impacting Molecular Diagnostics Market
3.6.4 Technological Factors Impacting Molecular Diagnostics Market
4 North America Molecular Diagnostics Market by Technology
4.1 Polymerase Chain Reaction Segment Market Forecast, 2021-2031
4.1.1 Technological Advancements to Fuel PCR Segment Growth
4.1.2 Polymerase Chain Reaction Market by Sub-Segment, 2021-2031
4.1.3 Recovery Scenarios (V, U, W, L)
4.2 In Situ Hybridization Segment Market Forecast, 2021-2031
4.2.1 Increasing Incidence of Genetic Disorder and Cancer to Boost ISH Market Growth
4.2.2 Recovery Scenarios (V, U, W, L)
4.3 Isothermal Nucleic Acid Amplification Technology Segment Market Forecast, 2021-2031
4.3.1 Rising Prevalence of Infectious Disease to Drive INAAT Market Growth
4.3.2 Recovery Scenarios (V, U, W, L)
4.4 Chips and Microarrays Segment Market Forecast, 2021-2031
4.4.1 Increasing Usage in Basic Molecular Biology to Drive Segmental Growth
4.4.2 Recovery Scenarios (V, U, W, L)
4.5 Mass Spectrometry Segment Market Forecast, 2021-2031
4.5.1 Multidimensional Analysis and Evaluation of Impurities During Drug Development Process Fuelling Market Growth
4.5.2 Recovery Scenarios (V, U, W, L)
4.6 Sequencing Segment Market Forecast, 2021-2031
4.6.1 Sequencing Segment to Offer Massive Advances in Diagnosis, Prognosis and Treatment of Disease
4.6.2 Recovery Scenarios (V, U, W, L)
4.7 Transcription Mediated Amplification Segment Market Forecast, 2021-2031
4.7.1 Recovery Scenarios (V, U, W, L)
4.8 Others Segment Market Forecast, 2021-2031
4.8.1 Recovery Scenarios (V, U, W, L)
5 North America Molecular Diagnostics Market by Application
5.1 Oncology Segment Market Forecast, 2021-2031
5.1.1 Rising Prevalence of Cancer to Propel Market Growth
5.1.2 Oncology Market by Sub-Segment, 2021-2031
5.1.3 Recovery Scenarios (V, U, W, L)
5.2 Pharmacogenomics Segment Market Forecast, 2021-2031
5.2.1 Increasing Importance Across Emerging Economies to Fuel Pharmacogenomics Market Growth
5.2.2 Recovery Scenarios (V, U, W, L)
5.3 Infectious Diseases Segment Market Forecast, 2021-2031
5.3.1 Technological Advancements to Propel Usage of Molecular Diagnostics for Infectious Diseases
5.3.2 Infectious Diseases Market by Sub-Segment, 2021-2031
5.3.3 Recovery Scenarios (V, U, W, L)
5.4 Genetic Testing Segment Market Forecast, 2021-2031
5.4.1 Genetic Testing Has Led to Expansion of Molecular Techniques Withing Clinical Laboratories
5.4.2 Genetic Testing Market by Sub-Segment, 2021-2031
5.4.3 Recovery Scenarios (V, U, W, L)
5.5 Neurological Disease Segment Market Forecast, 2021-2031
5.5.1 Molecular Diagnostics for Infectious Diseases to Witness Significant Growth
5.5.2 Recovery Scenarios (V, U, W, L)
5.6 Cardiovascular Diseases Segment Market Forecast, 2021-2031
5.6.1 Growing Burden of CVDs Across Emerging Economies to Fuel Segmental Market Growth
5.6.2 Recovery Scenarios (V, U, W, L)
5.7 Microbiology Segment Market Forecast, 2021-2031
5.7.1 Technological Advancements Fuelling Microbiology Segment Growth
5.7.2 Recovery Scenarios (V, U, W, L)
5.8 Others Segment Market Forecast, 2021-2031
5.8.1 Recovery Scenarios (V, U, W, L)
6 North America Molecular Diagnostics Market by Product
6.1 Instruments Segment Market Forecast, 2021-2031
6.1.1 Strong Demand from Emerging Economies for Advanced Instruments
6.1.2 Recovery Scenarios (V, U, W, L)
6.2 Reagents Segment Market Forecast, 2021-2031
6.2.1 Reagents Segment Accounts for Majority of the Market Share
6.2.2 Recovery Scenarios (V, U, W, L)
7 North America Molecular Diagnostics Market by Test Location
7.1 Point-of-Care Segment Market Forecast, 2021-2031
7.1.1 Recovery Scenarios (V, U, W, L)
7.2 Over the Counter Segment Market Forecast, 2021-2031
7.2.1 Recovery Scenarios (V, U, W, L)
7.3 Central Laboratories Segment Market Forecast, 2021-2031
7.3.1 Recovery Scenarios (V, U, W, L)
8 North America Molecular Diagnostics Market by Country
8.1 Largest Molecular Diagnostics Market Globally
8.2 North America Molecular Diagnostics Market by Country, Forecast 2021-2031
8.3 U.S. Molecular Diagnostics Market Forecast by Technology
8.3.1 Recovery Scenarios (V, U, W, L)
8.4 U.S. Molecular Diagnostics Market Forecast by Application
8.4.1 Recovery Scenarios (V, U, W, L)
8.5 U.S. Molecular Diagnostics Market Forecast by Product
8.5.1 Recovery Scenarios (V, U, W, L)
8.6 U.S. Molecular Diagnostics Market Forecast by Test Location
8.6.1 Recovery Scenarios (V, U, W, L)
8.7 U.S. Molecular Diagnostics Market Forecast, 2021-2031
8.7.1 U.S. Accounts for Majority of the North American Molecular Diagnostics Market
8.7.2 Recovery Scenarios (V, U, W, L): U.S. Molecular Diagnostics Market Forecast, 2021-2031
8.8 Canada Molecular Diagnostics Market Forecast by Technology
8.8.1 Recovery Scenarios (V, U, W, L)
8.9 Canada Molecular Diagnostics Market Forecast by Application
8.9.1 Recovery Scenarios (V, U, W, L)
8.10 Canada Molecular Diagnostics Market Forecast by Product
8.10.1 Recovery Scenarios (V, U, W, L)
8.11 Canada Molecular Diagnostics Market Forecast by Test Location
8.11.1 Recovery Scenarios (V, U, W, L)
8.12 Canada Molecular Diagnostics Market Forecast, 2021-2031
8.12.1 Rising Investments by Government to Spur Regional Market Growth
8.12.2 Recovery Scenarios (V, U, W, L): Canada Molecular Diagnostics Market Forecast, 2021-2031
9 Company Profiles
9.1 Roche Diagnostics
9.1.1 Company Snapshot
9.1.2 Company Overview
9.1.3 Financial Analysis
9.1.3.1 Net Revenue, 2015-2019
9.1.3.2 R&D Expenses, 2015-2019
9.1.3.3 Gross Profit, 2015-2019
9.1.3.4 Net Income, 2015-2019
9.1.3.5 EBDITA, 2015-2019
9.1.4 Product Benchmarking
9.1.5 Recent Developments, 2017-2020
9.2 Abbott
9.2.1 Company Snapshot
9.2.2 Company Overview
9.2.3 Financial Analysis
9.2.3.1 Net Revenue, 2015-2019
9.2.3.2 R&D Expenses, 2015-2019
9.2.3.3 Gross Profit, 2015-2019
9.2.3.4 Net Income, 2015-2019
9.2.3.5 EBDITA, 2015-2019
9.2.4 Product Benchmarking
9.3 Becton, Dickinson and Company
9.3.1 Company Snapshot
9.3.2 Company Overview
9.3.3 Financial Analysis
9.3.3.1 Net Revenue, 2015-2020
9.3.3.2 R&D Expenses, 2015-2020
9.3.3.3 Gross Profit, 2015-2020
9.3.3.4 Net Income, 2015-2020
9.3.3.5 EBDITA, 2015-2020
9.3.4 Product Benchmarking
9.3.5 Recent Developments, 2017-2020
9.4 bioMérieux SA
9.4.1 Company Snapshot
9.4.2 Company Overview
9.4.3 Financial Analysis
9.4.3.1 Net Revenue, 2016-2019
9.4.3.2 R&D Expenses, 2015-2019
9.4.3.3 Gross Profit, 2015-2019
9.4.3.4 Net Income, 2016-2019
9.4.3.5 EBDITA, 2015-2019
9.4.4 Product Benchmarking
9.4.5 Recent Developments, 2017-2020
9.5 Bio-Rad Laboratories, Inc.
9.5.1 Company Snapshot
9.5.2 Company Overview
9.5.3 Financial Analysis
9.5.3.1 Net Revenue, 2015-2019
9.5.3.2 R&D Expenses, 2015-2019
9.5.3.3 Gross Profit, 2015-2019
9.5.3.4 Net Income, 2015-2019
9.5.3.5 EBDITA, 2015-2019
9.5.4 Product Benchmarking
9.5.5 Recent Developments, 2017-2020
9.6 Dako (Agilent Technologies)
9.6.1 Company Snapshot
9.6.2 Company Overview
9.6.3 Financial Analysis
9.6.3.1 Net Revenue, 2015-2020
9.6.3.2 R&D Expenses, 2015-2020
9.6.3.3 Gross Profit, 2015-2020
9.6.3.4 Net Income, 2015-2020
9.6.3.5 EBDITA, 2015-2020
9.6.4 Product Benchmarking
9.6.5 Recent Developments, 2017-2020
9.7 Danaher
9.7.1 Company Snapshot
9.7.2 Company Overview
9.7.3 Financial Analysis
9.7.3.1 Net Revenue, 2015-2019
9.7.3.2 R&D Expenses, 2015-2019
9.7.3.3 Gross Profit, 2015-2019
9.7.3.4 Net Income, 2015-2019
9.7.3.5 EBDITA, 2015-2019
9.7.4 Product Benchmarking
9.8 FOUNDATION MEDICINE, INC.
9.8.1 Company Snapshot
9.8.2 Company Overview
9.8.3 Product Benchmarking
9.8.4 Recent Developments, 2017-2020
9.9 Genomic Health (Exact Sciences Corporation)
9.9.1 Company Snapshot
9.9.2 Company Overview
9.9.3 Financial Analysis
9.9.3.1 Net Revenue, 2015-2019
9.9.3.2 R&D Expenses, 2015-2019
9.9.3.3 Gross Profit, 2015-2019
9.9.3.4 Net Income, 2015-2019
9.9.3.5 EBDITA, 2015-2019
9.9.4 Product Benchmarking
9.9.5 Recent Developments, 2017-2020
9.10 Hologic, Inc.
9.10.1 Company Snapshot
9.10.2 Company Overview
9.10.3 Financial Analysis
9.10.3.1 Net Revenue, 2015-2020
9.10.3.2 R&D Expenses, 2015-2020
9.10.3.3 Gross Profit, 2015-2020
9.10.3.4 Net Income, 2015-2020
9.10.3.5 EBDITA, 2015-2020
9.10.4 Product Benchmarking
9.10.5 Recent Developments, 2017-2020
9.11 Illumina, Inc.
9.11.1 Company Snapshot
9.11.2 Company Overview
9.11.3 Financial Analysis
9.11.3.1 Net Revenue, 2015-2019
9.11.3.2 R&D Expenses, 2015-2019
9.11.3.3 Gross Profit, 2015-2019
9.11.3.4 Net Income, 2015-2019
9.11.3.5 EBDITA, 2015-2019
9.11.4 Product Benchmarking
9.11.5 Recent Developments, 2017-2020
9.12 HTG Molecular Diagnostics, Inc.
9.12.1 Company Snapshot
9.12.2 Company Overview
9.12.3 Financial Analysis
9.12.3.1 Net Revenue, 2015-2019
9.12.3.2 R&D Expenses, 2015-2019
9.12.3.3 Gross Profit, 2015-2019
9.12.3.4 Net Income, 2015-2019
9.12.3.5 EBDITA, 2015-2019
9.12.4 Product Benchmarking
9.12.5 Recent Developments, 2017-2020
9.13 Grifols, S.A.
9.13.1 Company Snapshot
9.13.2 Company Overview
9.13.3 Financial Analysis
9.13.3.1 Net Revenue, 2015-2019
9.13.3.2 R&D Expenses, 2015-2019
9.13.3.3 Gross Profit, 2015-2019
9.13.3.4 Net Income, 2015-2019
9.13.3.5 EBDITA, 2015-2019
9.13.4 Product Benchmarking
9.13.5 Recent Developments, 2017-2020
9.14 QIAGEN
9.14.1 Company Snapshot
9.14.2 Company Overview
9.14.3 Financial Analysis
9.14.3.1 Net Revenue, 2015-2019
9.14.3.2 R&D Expenses, 2015-2019
9.14.3.3 Gross Profit, 2015-2019
9.14.3.4 Net Income, 2015-2019
9.14.3.5 EBDITA, 2015-2019
9.14.4 Product Benchmarking
9.14.5 Recent Developments, 2017-2020
9.15 Siemens Healthcare GmbH
9.15.1 Company Snapshot
9.15.2 Company Overview
9.15.3 Financial Analysis
9.15.3.1 Net Revenue, 2015-2020
9.15.3.2 R&D Expenses, 2015-2020
9.15.3.3 Gross Profit, 2015-2020
9.15.3.4 Net Income, 2015-2020
9.15.3.5 EBDITA, 2015-2020
9.15.4 Product Benchmarking
9.16 Sysmex Corporation
9.16.1 Company Snapshot
9.16.2 Company Overview
9.16.3 Financial Analysis
9.16.3.1 Net Revenue, 2016-2020
9.16.3.2 Gross Profit, 2016-2020
9.16.3.3 Net Income, 2016-2020
9.16.3.4 EBDITA, 2016-2020
9.16.4 Product Benchmarking
9.16.5 Recent Developments, 2017-2020
10 Conclusion and Recommendations
10.1 Concluding Remarks
10.2 Recommendations



❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 分子診断(MDx)の北米市場2021年-2031年(North American Molecular Diagnostics (MDx) Market Report 2021-2031)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆